Quantcast

Latest Bristol-Myers Squibb Stories

2014-01-29 08:29:55

CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ -- Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (NYSE: BMY) for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Terms of agreement were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20140129/NE54258LOGO ) "It is a pleasure to...

2014-01-24 16:22:06

MIAMI, Jan. 24, 2014 /PRNewswire/ -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List. As a result of this new status,...

2014-01-18 08:20:15

Research findings enable disease molecular sub-typing to lead to more informed clinical decision-making IRVING, Texas, Jan. 18, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by...

2014-01-16 16:24:28

RARITAN, N.J., Jan. 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee has voted against the approval of the use of XARELTO(®) (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) in combination with standard antiplatelet therapy. Janssen is seeking approval of...

2014-01-14 16:26:57

QINGDAO, China and ROCKVILLE, Md., Jan. 14, 2014 /PRNewswire/ -- Synutra International, Inc. (NASDAQ: SYUT), ("Synutra" or the "Company"), which owns subsidiaries in China that produce, market and sell nutritional products for infants, children and adults, announced the commencement of construction of its new drying facility in Carhaix, France (located in the department of Finistere in the Brittany region). On January 10, 2014, the Company held a ground-breaking ceremony in Carhaix,...

FDA Approves Novel AstraZeneca, Bristol-Meyers Squibb Diabetes Drug
2014-01-10 11:37:58

Ranjini Raghunath for redOrbit.com - Your Universe Online The FDA has approved the use of a new Type 2 diabetes drug called Farxiga, developed by pharmaceutical companies Bristol-Meyers Squibb and AstraZeneca. Type 2 diabetes affects 24 million people in the US and nearly 350 million people worldwide. Conventional diabetes drugs work by reducing the amount of sugar the body absorbs from food or by boosting the production of insulin which disposes of excess sugar. Farxiga, however,...

2014-01-09 08:26:49

Pharma Industry Veteran Brings Full-Spectrum Healthcare Expertise to One of Venture Industry's Most Active Life Sciences Investors CHEVY CHASE, Md. and MENLO PARK, Calif., Jan. 9, 2014 /PRNewswire/ -- New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the appointment of Elliott Sigal, M.D., Ph.D. as Venture Partner and Senior Advisor. Dr. Sigal is a former Executive Vice President and Director for Bristol-Myers Squibb. He served as the...

2014-01-09 08:23:54

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 9, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), AmerisourceBergen Corporation (NYSE: ABC), and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access these reports free of charge -...

2014-01-09 00:21:30

- First approved combination of oral targeted therapies for unresectable or metastatic melanoma with BRAF V600E or V600K mutations[1] LONDON, Jan. 8, 2014 /PRNewswire/ -- GlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist(® )(trametinib) for use in combination with Tafinlar(®) (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related